Publications

Featured Publications

INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

COVID-19

Title Disease Target Product
Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020
COVID-19 INO-4800
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases — December 2021
COVID-19 INO-4800
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
The Journal of Infectious Diseases — January 2022
COVID-19 INO-4800
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
npj Vaccines — October 2021
COVID-19 INO-4800